Educational film, April 2023 // Amgen buys Horizon: Acquisitions, taxes and confidentiality
Giant big pharma bidding war
A rich analysis of the most recent acquisition in the world of pharmaceuticals when American independent biotech giant Amgen buys biopharmaceutical company Horizon Therapeutics for close to 28 billion dollars.
The process involved a huge bidding war between Johnson & Johnson, Sanofi and Amgen who had to raise considerably its offer. Horizon is deeply involved in rare disease drug creation.
With the deal, Amgen gets its hands on thyroid eye disease drug Tepezza, chronic gout treatment Krystexxa and Uplizna, a relatively new therapy that treats neuromyelitis optica spectrum disorder.
WEBVTT
1
00:00:07.600 --> 00:00:10.600
Hello and welcome to this film which is devoted to
2
00:00:10.600 --> 00:00:14.600
the acquisition by Amgen of horizon therapatics.
3
00:00:13.600 --> 00:00:16.100
We are in an industry which
4
00:00:16.100 --> 00:00:19.200
is name Pharmaceuticals. And it seems that they are
5
00:00:19.200 --> 00:00:22.600
plenty of acquisition in the right time for shopping in
6
00:00:22.600 --> 00:00:23.800
the Biotech Industry.
7
00:00:24.500 --> 00:00:27.400
You all remember about fights a fighter made
8
00:00:27.400 --> 00:00:31.000
a lot of money on the vaccines against the covid-19
9
00:00:30.300 --> 00:00:33.700
when you make a lot of money. What
10
00:00:33.700 --> 00:00:36.500
can you do? You can return the cash to the shareholders or
11
00:00:36.500 --> 00:00:39.100
you can reinvest in the development of the company.
12
00:00:39.800 --> 00:00:43.300
Invest and grow research development
13
00:00:42.300 --> 00:00:45.800
Acquisitions and so on and basically
14
00:00:45.800 --> 00:00:48.800
it is a solution which has been adopted the
15
00:00:48.800 --> 00:00:52.000
strategy of Pfizer Pfizer announced
16
00:00:51.100 --> 00:00:55.200
in October 2022 the acquisition of biohaven
17
00:00:54.200 --> 00:00:57.500
for 11.6 billion dollars
18
00:00:57.500 --> 00:01:00.400
and very recently in March the acquisition
19
00:01:00.400 --> 00:01:03.300
of CJ and for 43 billion
20
00:01:03.300 --> 00:01:07.000
dollars. Now when you get cash from something which
21
00:01:06.100 --> 00:01:10.100
is maybe exceptional hopefully the question
22
00:01:09.100 --> 00:01:13.000
is what do you do with the Monet again return
23
00:01:12.300 --> 00:01:15.400
or invest traditional story
24
00:01:15.400 --> 00:01:19.400
now Amgen is offering 27.8 billion
25
00:01:18.400 --> 00:01:21.500
dollars for Horizon to
26
00:01:21.500 --> 00:01:24.900
Rapides. It was announced in December 2022 and
27
00:01:24.900 --> 00:01:27.700
it is ongoing. The reason for Amgen
28
00:01:27.700 --> 00:01:30.500
to buy Horizon is they want to develop
29
00:01:30.500 --> 00:01:33.900
they want to expand in rare diseases treatments.
30
00:01:35.100 --> 00:01:38.700
Us strategy now, I'm Jen was created and
31
00:01:38.700 --> 00:01:41.800
established around 1980 and
32
00:01:41.800 --> 00:01:44.300
they received the first FDA approval
33
00:01:44.300 --> 00:01:47.400
online 1989 for a drug
34
00:01:47.400 --> 00:01:48.700
with name was epogen.
35
00:01:49.400 --> 00:01:52.200
You understand that in the pharmaceutical industry. It takes
36
00:01:52.200 --> 00:01:55.300
time before the mermaid you start investing in research
37
00:01:55.300 --> 00:01:58.600
and development and getting through phase one two, three
38
00:01:58.600 --> 00:02:01.700
and approval it takes time. And then in
39
00:02:01.700 --> 00:02:04.000
the meantime, you have all these products which are in the
40
00:02:04.200 --> 00:02:07.600
pipeline. The company is in a technology,
41
00:02:07.600 --> 00:02:10.500
which is his name recombinant DNA. It's
42
00:02:10.500 --> 00:02:13.700
about biotech. It's about genetics. The
43
00:02:13.700 --> 00:02:16.600
company has been quite successful so far. They
44
00:02:16.600 --> 00:02:20.000
had a little bit of accident in 2012 because the
45
00:02:19.400 --> 00:02:22.600
campaign was accused of making some
46
00:02:22.600 --> 00:02:26.500
indications proposing to customers indications,
47
00:02:25.500 --> 00:02:28.300
which had not been approved by
48
00:02:28.300 --> 00:02:32.100
the FDA and illegal marketing practices
49
00:02:31.100 --> 00:02:35.100
a company had to pay one hand and 50 million
50
00:02:34.100 --> 00:02:38.800
dollars for penalties and 612
51
00:02:37.800 --> 00:02:40.300
million dollars to close all
52
00:02:40.300 --> 00:02:43.400
the complaints related with this really bad
53
00:02:43.400 --> 00:02:46.400
process. That being said the company developed
54
00:02:46.400 --> 00:02:48.700
a strategy which consists in R&D.
55
00:02:49.400 --> 00:02:53.300
Are a debit also plenty of Acquisitions companies firms
56
00:02:52.300 --> 00:02:55.000
cooperations and formulas.
57
00:02:55.800 --> 00:02:58.900
To give you some examples 2015 the Zima
58
00:02:58.900 --> 00:03:02.600
for 1.6 billion biringer ingelheim's
59
00:03:01.600 --> 00:03:04.600
the myeloma treatment in
60
00:03:04.600 --> 00:03:07.900
2016 2017 celga
61
00:03:07.900 --> 00:03:11.400
and the old Sarah program for 13.4
62
00:03:10.400 --> 00:03:14.000
billion 20.5% of
63
00:03:13.300 --> 00:03:16.700
by Gene Beijing which
64
00:03:16.700 --> 00:03:19.800
is a kind of phonetical joke because
65
00:03:19.800 --> 00:03:23.200
a company is located in Beijing for
66
00:03:22.200 --> 00:03:25.400
2.7 billion. It was in 20
67
00:03:25.400 --> 00:03:29.100
20 21 five prime plus plus four three
68
00:03:28.100 --> 00:03:31.200
point five billion. And the last
69
00:03:31.200 --> 00:03:34.000
one last year camel Centrics for three point seven
70
00:03:34.400 --> 00:03:37.200
billion. Now Horizon is much more but you know,
71
00:03:37.200 --> 00:03:40.800
it's a kind of continuation in investment. You
72
00:03:40.800 --> 00:03:43.800
can consider that the company is very much investing
73
00:03:43.800 --> 00:03:46.300
but it's also returning plenty of cash to
74
00:03:46.300 --> 00:03:49.900
shareholders. And so far the sales the
75
00:03:49.900 --> 00:03:52.000
revenue are not growing at a high rate
76
00:03:52.400 --> 00:03:55.600
the kagger increasing sales. I'm Jen
77
00:03:55.600 --> 00:03:55.700
from
78
00:03:55.800 --> 00:03:58.800
2019 to 2022 is
79
00:03:58.800 --> 00:04:01.300
just 4% per year and it
80
00:04:01.300 --> 00:04:04.200
was less last year. So of course there is a
81
00:04:04.200 --> 00:04:07.800
list of Acquisitions and if you take these four years the sub
82
00:04:07.800 --> 00:04:10.300
up to 23 billion dollars, but in the meantime,
83
00:04:10.300 --> 00:04:13.800
we share BuyBacks during the same years and
84
00:04:13.800 --> 00:04:16.900
dividend so cash return to shareholders account for
85
00:04:16.900 --> 00:04:19.500
38 billion. So 15 billion
86
00:04:19.500 --> 00:04:22.400
more given back to shareholders as opposed to
87
00:04:22.400 --> 00:04:24.300
reinvested in business operations.
88
00:04:25.100 --> 00:04:28.400
It's quite important to understand where the company stands today.
89
00:04:28.400 --> 00:04:31.400
Now if you compare and Benchmark, I'm Jen
90
00:04:31.400 --> 00:04:34.500
and Horizon. Amgen is bigger the sales
91
00:04:34.500 --> 00:04:37.700
in 2022 where 26 billion and
92
00:04:37.700 --> 00:04:40.600
for Horizon 3.6 billion. We'll
93
00:04:40.600 --> 00:04:42.400
see in a minute based on one product.
94
00:04:43.200 --> 00:04:46.500
But the sales grows, he's just 1% at Amgen when
95
00:04:46.500 --> 00:04:50.400
it is 12% currently for Horizon a
96
00:04:49.400 --> 00:04:53.200
discussion on growth is for layer. Now
97
00:04:52.200 --> 00:04:55.800
on a commercial point of in terms of returns sales.
98
00:04:55.800 --> 00:04:58.300
The return sales is much higher than
99
00:04:58.300 --> 00:05:01.800
the one for Horizon. So 36% as
100
00:05:01.800 --> 00:05:04.800
opposed to 17% the return Capital
101
00:05:04.800 --> 00:05:08.400
you remember the performance indicator is 29%
102
00:05:07.400 --> 00:05:10.600
and only 12% for
103
00:05:10.600 --> 00:05:11.600
Horizon.
104
00:05:12.400 --> 00:05:15.400
But you remember that to calculate the return Capital you
105
00:05:15.400 --> 00:05:18.600
divide the operating income a bit by Capital employed in
106
00:05:18.600 --> 00:05:21.500
the capital employed you have good. Will you
107
00:05:21.500 --> 00:05:24.800
are Branch you have catalyzed R&D acquired R&D
108
00:05:24.800 --> 00:05:27.500
and so on so forth. So the consequence of Acquisitions, if
109
00:05:27.500 --> 00:05:30.300
you get rid of that in the calculation of
110
00:05:30.300 --> 00:05:33.700
the capital employed you get to something which is operating Capital
111
00:05:33.700 --> 00:05:36.700
employed and then you can calculate the return
112
00:05:36.700 --> 00:05:40.600
which is generated by your business operations. Whatever
113
00:05:39.600 --> 00:05:42.100
the cost you paid for
114
00:05:42.100 --> 00:05:45.700
the Acquisitions and then it kind of return on investment. I
115
00:05:45.700 --> 00:05:48.400
often name that return investment. It's more
116
00:05:48.400 --> 00:05:51.600
than 500% for MJ. So you
117
00:05:51.600 --> 00:05:54.900
understand that what is penalizing the company is Goodwill and
118
00:05:54.900 --> 00:05:57.300
Brands and capitalize are the and so
119
00:05:57.300 --> 00:06:01.000
on so forth. The return investment for Horizon is only quotes
120
00:06:00.900 --> 00:06:03.700
78% which is still very
121
00:06:03.700 --> 00:06:06.100
high the consequence of all these
122
00:06:06.100 --> 00:06:10.600
metrics is that the market cap for ham Jen is 129 billion.
123
00:06:10.600 --> 00:06:12.300
It's a very big company with
124
00:06:12.400 --> 00:06:15.700
Wrong capitalization as far as Horizon to
125
00:06:15.700 --> 00:06:18.900
Rapides is concerned the market cap was 14 billion
126
00:06:18.900 --> 00:06:21.800
before the offer made by Amgen
127
00:06:21.800 --> 00:06:24.900
and today it's 25 billion dollars. So
128
00:06:24.900 --> 00:06:27.500
it's smaller. That's quite normal
129
00:06:27.500 --> 00:06:28.900
if you look at the metrics.
130
00:06:30.300 --> 00:06:33.300
We had a look at the story of Amgen. Now
131
00:06:33.300 --> 00:06:36.700
Horizon therapatics is a very specific Company. The
132
00:06:36.700 --> 00:06:39.900
company was created in 2004 by
133
00:06:39.900 --> 00:06:43.000
a gentleman whose name is Tim Walbert is
134
00:06:42.900 --> 00:06:46.000
chairman of the board chief executive officer
135
00:06:45.600 --> 00:06:48.500
founder and customer and
136
00:06:48.500 --> 00:06:52.100
patient now at the origin of horizon zerapatics,
137
00:06:51.100 --> 00:06:54.700
there's the idea of Team Wahlberg and
138
00:06:54.700 --> 00:06:57.700
the idea comes from the fact that is suffering from
139
00:06:57.700 --> 00:07:00.800
these rare diseases. One
140
00:07:00.800 --> 00:07:03.700
of them only want to develop an offer a
141
00:07:03.700 --> 00:07:06.800
portfolio of treatments for these rare diseases.
142
00:07:06.800 --> 00:07:09.300
You understand the communication point of
143
00:07:09.300 --> 00:07:12.400
view that when the CEO says I am the one
144
00:07:12.400 --> 00:07:16.000
who is using the same treatment as you the customers,
145
00:07:15.500 --> 00:07:17.400
this is quite strong.
146
00:07:18.300 --> 00:07:21.400
Now the company is very much based in the United States
147
00:07:21.400 --> 00:07:24.500
97% of sales and revenues
148
00:07:24.500 --> 00:07:27.500
are generated by the company in the United States, but
149
00:07:27.500 --> 00:07:31.300
the company's paying its taxes in Ireland because
150
00:07:30.300 --> 00:07:33.600
in 2014 the company runs
151
00:07:33.600 --> 00:07:36.800
something which is never tax inversion and they
152
00:07:36.800 --> 00:07:40.500
did it three days before all the legislation changes about
153
00:07:39.500 --> 00:07:42.900
these possibility to change
154
00:07:42.900 --> 00:07:45.400
the localization of the head office. In fact
155
00:07:46.400 --> 00:07:49.500
Horizon acquired vidara Therapeutics in
156
00:07:49.500 --> 00:07:52.500
Ireland for 660 million dollars. This
157
00:07:52.500 --> 00:07:55.200
is not the important figure and they moved
158
00:07:55.200 --> 00:07:58.200
the head office to Ireland at the consequence. Now
159
00:07:58.200 --> 00:08:02.100
the company's paying taxes on the basis of 15% as
160
00:08:01.100 --> 00:08:04.500
opposed to 35% at that
161
00:08:04.500 --> 00:08:07.700
time. When you save 20% of tax, what
162
00:08:07.700 --> 00:08:10.500
do you do with the money it's cash which is available. And the
163
00:08:10.500 --> 00:08:13.400
company says I pay less taxes. I
164
00:08:13.400 --> 00:08:16.500
have more cash available to make Acquisitions for
165
00:08:16.500 --> 00:08:19.800
the sake and the wealth of my dear beloved shareholders.
166
00:08:19.800 --> 00:08:22.500
Now, you understand that there are some questions behind that
167
00:08:22.500 --> 00:08:25.600
put yourself in the shoes of the US government.
168
00:08:26.600 --> 00:08:29.400
You're in charge of trying to prevent the
169
00:08:29.400 --> 00:08:33.300
companies to move from USA to anywhere
170
00:08:32.300 --> 00:08:35.700
else kinds of tax Havens, right?
171
00:08:35.700 --> 00:08:38.700
What would you recommend to change in the
172
00:08:38.700 --> 00:08:42.300
legislation? Would you recommend to change the law unforbids
173
00:08:41.300 --> 00:08:44.500
this kind of process now, it's forbidden
174
00:08:44.500 --> 00:08:47.700
and you're not allowed to move your head office tax Wise
175
00:08:47.700 --> 00:08:50.500
from I don't know, New York to Dublin.
176
00:08:51.600 --> 00:08:54.500
Second alternative. Do you reduce the
177
00:08:54.500 --> 00:08:57.300
corporate tax rate? So that companies have
178
00:08:57.300 --> 00:09:00.400
less motivation to move abroad you
179
00:09:00.400 --> 00:09:03.400
understand that if the situation is currently 35 as opposed
180
00:09:03.400 --> 00:09:06.300
to 15. The motivation is high if it
181
00:09:06.300 --> 00:09:09.200
is 25 or 20 the motivation is
182
00:09:09.200 --> 00:09:12.300
less because it's costly to move the head
183
00:09:12.300 --> 00:09:12.600
office.
184
00:09:13.500 --> 00:09:17.000
Now, of course, there's no one best
185
00:09:16.400 --> 00:09:19.500
way but just take a couple of minutes thinking
186
00:09:19.500 --> 00:09:22.800
about the implications of these
187
00:09:22.800 --> 00:09:25.600
two Alternatives. If you decide to implement one
188
00:09:25.600 --> 00:09:28.700
as opposed to the other, it's quite an interesting
189
00:09:28.700 --> 00:09:31.300
intellectual process. Now, let's move
190
00:09:31.300 --> 00:09:34.100
on with Horizon Therapeutics. The capital is paying
191
00:09:34.100 --> 00:09:37.700
less taxes. So the company holds more cash. What do
192
00:09:37.700 --> 00:09:41.600
you do with the cash make Acquisitions Hyperion torapatics
193
00:09:40.600 --> 00:09:43.700
for one point something billion in 20
194
00:09:43.700 --> 00:09:46.400
15 one year after the tax
195
00:09:46.400 --> 00:09:49.700
inversion earlier Raptor pharmaceutical for
196
00:09:49.700 --> 00:09:53.200
0.6 billion recently the lrbo
197
00:09:52.200 --> 00:09:54.700
for 3 billion.
198
00:09:55.300 --> 00:09:58.600
Interestingly the company tried to take over
199
00:09:58.600 --> 00:10:01.200
Diplomat and Diplomat. It
200
00:10:01.200 --> 00:10:05.400
was not successful at all in 2015 Horizon
201
00:10:04.400 --> 00:10:07.500
is offering three billion dollars
202
00:10:07.500 --> 00:10:10.200
thirty three dollars per share.
203
00:10:10.200 --> 00:10:13.100
Remember this figure to buy 100% of
204
00:10:13.100 --> 00:10:16.900
Diplomat shares. The offer is rejected by the board of Diplomat
205
00:10:16.900 --> 00:10:19.300
this as a price is not high enough, of course,
206
00:10:19.300 --> 00:10:22.500
they always say that but they are also going to implement
207
00:10:22.500 --> 00:10:26.300
a poison pill which is named shareholders rights
208
00:10:25.300 --> 00:10:28.000
plan. If there is
209
00:10:28.200 --> 00:10:31.300
a whole style take over and if a Raider holds most and 10%
210
00:10:31.300 --> 00:10:34.400
of the share, you are allowed to flood the market with new
211
00:10:34.400 --> 00:10:37.900
shares diluting the process and that's just impossible
212
00:10:37.900 --> 00:10:39.000
to buy the company.
213
00:10:39.800 --> 00:10:42.500
But this is about a poison pill it was nicely
214
00:10:42.500 --> 00:10:45.600
complemented and supported by a decision
215
00:10:45.600 --> 00:10:48.700
taken by the superior court of justice in
216
00:10:48.700 --> 00:10:51.300
California. And the quarter just
217
00:10:51.300 --> 00:10:54.500
said, hey, you know Horizon you
218
00:10:54.500 --> 00:10:58.200
use some confidential information to
219
00:10:57.200 --> 00:11:00.400
prepare your takeover on Diplomat,
220
00:11:00.400 --> 00:11:03.300
which is absolutely ill. You're not
221
00:11:03.300 --> 00:11:06.200
allowed to do that. And this is why there was this kind
222
00:11:06.200 --> 00:11:09.300
of Justice decision, which was a nice compliment to
223
00:11:09.300 --> 00:11:12.000
the poison pill. What was the story about?
224
00:11:12.800 --> 00:11:15.900
A few years before Horizon and
225
00:11:15.900 --> 00:11:18.600
Diplomat they made an offer joint
226
00:11:18.600 --> 00:11:22.400
offer to buy from Johnson & Johnson a portfolio
227
00:11:21.400 --> 00:11:24.800
products including Nucynta.
228
00:11:25.500 --> 00:11:28.200
The art field was rejected the withdraw the
229
00:11:28.200 --> 00:11:31.500
offer whatever end of the story but in
230
00:11:31.500 --> 00:11:35.000
order to make the offer you need Horizon to
231
00:11:34.300 --> 00:11:37.600
know a little bit about papermed and diplomed a
232
00:11:37.600 --> 00:11:40.900
little bit about Horizon. So you have access to confidential information. Of
233
00:11:40.900 --> 00:11:43.100
course, you sign an NDA and so on so forth,
234
00:11:43.100 --> 00:11:46.300
but you know, what is happening in the culture of
235
00:11:46.300 --> 00:11:50.000
your beloved neighbor later on Diplomat bold
236
00:11:49.600 --> 00:11:52.100
Lucinda, which was part of the portfolio and they
237
00:11:52.100 --> 00:11:55.700
had one billion dollars lucinta is
238
00:11:55.700 --> 00:11:58.600
a painkiller but it belongs to a
239
00:11:58.600 --> 00:12:02.100
family of product which is named opioids. All
240
00:12:01.100 --> 00:12:04.400
right, and so the Wall Street
241
00:12:04.400 --> 00:12:07.000
Journal are not already in 2015. Well say, you
242
00:12:07.900 --> 00:12:10.400
know opioid it's it's a cash cow, but it's
243
00:12:10.400 --> 00:12:13.700
a little bit of problem on a technological unhealth point
244
00:12:13.700 --> 00:12:16.400
of views are plenty of Critics on that now
245
00:12:16.400 --> 00:12:19.600
Diplomat by his new center and wants to
246
00:12:19.600 --> 00:12:22.000
fully benefit from Lucinda.
247
00:12:22.700 --> 00:12:25.400
And says that service regards per share does not
248
00:12:25.400 --> 00:12:28.500
reflect the true value of new center and they are
249
00:12:28.500 --> 00:12:31.500
right because when Horizon makes the
250
00:12:31.500 --> 00:12:34.200
offer it is at 33 dollars a few months
251
00:12:34.200 --> 00:12:37.800
later mid 2015 and of
252
00:12:37.800 --> 00:12:40.300
2015 the stock price reaches a
253
00:12:40.300 --> 00:12:43.200
high of 125 dollars per share.
254
00:12:43.200 --> 00:12:46.500
This is why Diplomat rejected the board
255
00:12:46.500 --> 00:12:50.100
rejected the offer but nucinta
256
00:12:49.100 --> 00:12:52.300
is part of opioid and you
257
00:12:52.300 --> 00:12:55.400
know all the problems related with that with plenty of
258
00:12:55.400 --> 00:12:56.100
death.
259
00:12:56.900 --> 00:12:59.600
This is why later on Diplomat had
260
00:12:59.600 --> 00:13:02.700
to sell Nucynta for 10 million dollars
261
00:13:02.700 --> 00:13:06.700
acquired one billion dollars Diplomat
262
00:13:05.700 --> 00:13:08.300
was really very much in
263
00:13:08.300 --> 00:13:11.700
trouble. They change the name of the company as they moved to assess
264
00:13:11.700 --> 00:13:14.100
you changing. The name does not get rid of problems and
265
00:13:14.100 --> 00:13:17.500
issues and today currently the stock price is six
266
00:13:17.500 --> 00:13:18.500
dollars per share.
267
00:13:19.200 --> 00:13:23.000
But at the end of the day, it was probably not a bad news for Horizon not
268
00:13:22.500 --> 00:13:24.600
to buy the permit.
269
00:13:25.100 --> 00:13:28.100
But let's go back to Horizon. Now. There is an
270
00:13:28.100 --> 00:13:32.200
acquisition. There's a price. Let's try to evaluate the company to evaluate
271
00:13:31.200 --> 00:13:34.400
a company you use a free cash flows, which
272
00:13:34.400 --> 00:13:37.600
you discount at the weighted average cost of capital free cash
273
00:13:37.600 --> 00:13:40.100
flows. The formula is very well known it's a bit
274
00:13:40.100 --> 00:13:44.000
I minus change in working capital requirement inventories and
275
00:13:43.500 --> 00:13:46.700
receivables that have payables minus Capital expenditures
276
00:13:46.700 --> 00:13:49.600
minus taxes you pay on their bit. You
277
00:13:49.600 --> 00:13:52.200
take their current a bit. It's what I
278
00:13:52.200 --> 00:13:55.300
did by the way in terms of Delta increase in
279
00:13:55.300 --> 00:13:58.100
the working capital requirement. I can't commit to
280
00:13:58.100 --> 00:14:02.000
the working capital requirement which I'm multiplied by the current growth rate
281
00:14:01.300 --> 00:14:04.500
of the revenues to our present
282
00:14:04.500 --> 00:14:07.100
Capital expenditures. It's about 2% to
283
00:14:07.100 --> 00:14:09.700
sales. It's not very Capital intensive. It's kind of business.
284
00:14:10.700 --> 00:14:13.600
The free cash flow which you get after this calculation is
285
00:14:13.600 --> 00:14:15.800
880 million dollars.
286
00:14:16.700 --> 00:14:19.300
Now this free cash flow has to be discounted and
287
00:14:19.300 --> 00:14:20.700
the way the average cost of capital.
288
00:14:21.600 --> 00:14:24.300
You remember cost of equity time share of
289
00:14:24.300 --> 00:14:27.700
equity cost of that time share of that share of that Neil almost
290
00:14:27.700 --> 00:14:30.100
zero. So the walk is the cost of
291
00:14:30.100 --> 00:14:33.000
equity to calculate the cost of equity. You need to know
292
00:14:33.200 --> 00:14:36.200
the government born. Right and you're going to add a risk
293
00:14:36.200 --> 00:14:39.300
premium, which is a beta the systematic risk coefficient.
294
00:14:39.300 --> 00:14:42.300
You remember the correlation to stock market index which
295
00:14:42.300 --> 00:14:45.100
is supposedly the correlation between the value of the
296
00:14:45.100 --> 00:14:48.600
company and macroeconomy conditions and the beta
297
00:14:48.600 --> 00:14:52.100
is multiplied by the average historical Market risk premium.
298
00:14:52.800 --> 00:14:55.400
The beta as you see on the graph is about
299
00:14:55.400 --> 00:14:58.300
one 36 months beta you
300
00:14:58.300 --> 00:15:01.400
remember the 12 months beta is much more for a time. It's quite
301
00:15:01.400 --> 00:15:04.700
stable around one. No big deal about the calculation
302
00:15:04.700 --> 00:15:08.000
work again is cost of equity garment
303
00:15:07.300 --> 00:15:11.200
bone rate currently about 3.4 6%
304
00:15:10.200 --> 00:15:13.300
for the equity Market which premium which you
305
00:15:13.300 --> 00:15:17.900
multiply by one to add 3.4 and you get 9.4% again,
306
00:15:17.900 --> 00:15:20.400
the cost of capital does not include any cost of
307
00:15:20.400 --> 00:15:23.600
that now once you have calculated the weighted
308
00:15:23.600 --> 00:15:26.400
average cost of capital and calculated the
309
00:15:26.400 --> 00:15:29.300
current cash flow, you can discount the free
310
00:15:29.300 --> 00:15:31.900
cash flows which are going to be generated by the company in the future.
311
00:15:33.200 --> 00:15:36.100
But then there are two situations if the company
312
00:15:36.100 --> 00:15:39.400
is at maturity the free cash flow is going to smoothly grow
313
00:15:39.400 --> 00:15:42.200
by G percentage and every year and then you
314
00:15:42.200 --> 00:15:45.400
have a beautiful formula which tells you that the Enterprise Value
315
00:15:45.400 --> 00:15:48.100
is a kind of terminal value because you are
316
00:15:48.100 --> 00:15:51.100
at maturity. It's free cash flow to the multiplied by 1 plus
317
00:15:51.100 --> 00:15:54.800
rows divided by walk less grows. If
318
00:15:54.800 --> 00:15:57.500
you remember a bit about many many eggs, it's about
319
00:15:57.500 --> 00:16:00.200
geometric series one plus X Plus x
320
00:16:00.200 --> 00:16:03.700
to the second power blah blah, which is converging towards
321
00:16:03.700 --> 00:16:06.300
the formula which shows on the screen.
322
00:16:06.300 --> 00:16:08.500
Now the question is, what about the growth rate?
323
00:16:09.500 --> 00:16:12.500
And then you have to Alternatives, you know,
324
00:16:12.500 --> 00:16:16.000
the price rate you calculate the Enterprise Value, you know,
325
00:16:15.200 --> 00:16:18.800
the Enterprise Value, then you can calculate the underlying
326
00:16:18.800 --> 00:16:21.300
growth rate which justifies the Enterprise
327
00:16:21.300 --> 00:16:22.700
Value on the stock market.
328
00:16:23.700 --> 00:16:26.400
If you take a stock price of $62
329
00:16:26.400 --> 00:16:29.300
per share, which is a pre takeover price.
330
00:16:30.100 --> 00:16:33.400
It represents an Enterprise value of 14.4 billion dollars,
331
00:16:33.400 --> 00:16:36.400
which is justified by a kind
332
00:16:36.400 --> 00:16:38.800
of underline growth of 3.3%
333
00:16:39.900 --> 00:16:43.300
Three percent it's less than inflation today. It's
334
00:16:42.300 --> 00:16:45.600
a kind of History called inflation rate for
335
00:16:45.600 --> 00:16:48.400
the United States. So you understand that at the
336
00:16:48.400 --> 00:16:51.900
end of the day. The company was probably under revolved
337
00:16:51.900 --> 00:16:52.600
with it by the market.
338
00:16:54.200 --> 00:16:57.500
If you take the offered price for the Takeover, the Enterprise Value
339
00:16:57.500 --> 00:17:00.400
is about 27 billion dollars.
340
00:17:01.500 --> 00:17:04.900
And then it is justified by a growth
341
00:17:04.900 --> 00:17:09.200
in our revenues by 6.1% 6.1
342
00:17:07.200 --> 00:17:10.400
is kind of inflation plus
343
00:17:10.400 --> 00:17:13.200
GDP grows. No big deal about
344
00:17:13.200 --> 00:17:16.400
that. The problem about the calculation is that the company's
345
00:17:16.400 --> 00:17:19.900
definitely not at maturity yet. This
346
00:17:19.900 --> 00:17:22.000
is why you need a second method which is a little bit
347
00:17:22.300 --> 00:17:25.800
more sophisticated. It's a two-step model first
348
00:17:25.800 --> 00:17:29.200
high growth second. Maturity Enterprise
349
00:17:28.200 --> 00:17:31.500
Value is a present value of the cash
350
00:17:31.500 --> 00:17:34.400
flows when the company is fast growing plus the terminal
351
00:17:34.400 --> 00:17:37.200
value of the company you use the same formula with a free
352
00:17:37.200 --> 00:17:40.500
cash flow divided by workplace grows, which you discount
353
00:17:41.300 --> 00:17:44.300
No big deal. The question is what is a growth during
354
00:17:44.300 --> 00:17:47.000
this first phase and what will be the growth in the long term?
355
00:17:47.700 --> 00:17:50.300
I took 12% for the next 10 years,
356
00:17:50.300 --> 00:17:53.900
which is a current growth rate. And I took 2.5% which
357
00:17:53.900 --> 00:17:56.400
is a little bit less than inflation for the
358
00:17:56.400 --> 00:17:59.300
terminal value calculation and at the end of the day, what
359
00:17:59.300 --> 00:18:02.400
do you get you get the same Enterprise Value as a one which
360
00:18:02.400 --> 00:18:04.600
is offered today by Amgen.
361
00:18:05.400 --> 00:18:08.500
110 dollars per share as supposed to one hand
362
00:18:08.500 --> 00:18:11.200
16.5 now you understand that the price which
363
00:18:11.200 --> 00:18:14.300
is offered by mg and is consistent with you keep on
364
00:18:14.300 --> 00:18:17.200
growing at 12% and then a terminal
365
00:18:17.200 --> 00:18:20.500
value. It takes into account 2.5% looks quite
366
00:18:20.500 --> 00:18:21.100
reasonable.
367
00:18:22.100 --> 00:18:25.500
But the question is is it the right way to evaluate a
368
00:18:25.500 --> 00:18:27.400
company in pharmaceutical industry?
369
00:18:28.300 --> 00:18:31.200
When you want to evaluate a company, there's a kind of general rule.
370
00:18:31.200 --> 00:18:34.200
The value for company is the sum of the
371
00:18:34.200 --> 00:18:37.800
value of the existing embedded assets put
372
00:18:37.800 --> 00:18:39.100
the value of growth options.
373
00:18:39.900 --> 00:18:42.700
To make it simple. The existing assets are
374
00:18:42.700 --> 00:18:45.200
generating the current and near future
375
00:18:45.200 --> 00:18:48.800
free cash flows. But in a long time the value
376
00:18:48.800 --> 00:18:51.400
of the company is about exercising growth
377
00:18:51.400 --> 00:18:54.600
options. This is I identifying projects
378
00:18:54.600 --> 00:18:57.500
and implementing the growth options, which is going to generate
379
00:18:57.500 --> 00:18:59.400
long term free cash flows.
380
00:19:00.300 --> 00:19:03.400
What about these growth option? It's about competences. It's about
381
00:19:03.400 --> 00:19:06.300
skills. It's about Rd. It's about human capital. It's
382
00:19:06.300 --> 00:19:09.400
about reputation The credibility of your industry and
383
00:19:09.400 --> 00:19:12.700
The credibility of the company within the industry. All these
384
00:19:12.700 --> 00:19:15.600
assets are intangible assets. It
385
00:19:15.600 --> 00:19:18.600
does nothing to do with property plant and equipment in
386
00:19:18.600 --> 00:19:21.500
order to understand the difference between an existing asset
387
00:19:21.500 --> 00:19:23.900
and a growth option. There's an interesting case.
388
00:19:24.800 --> 00:19:27.700
You remember any Academy? We studied the
389
00:19:27.700 --> 00:19:30.600
acquisition of farmer said by Gilead the
390
00:19:30.600 --> 00:19:33.900
treatment which had been developed by pharmaceut was extremely
391
00:19:33.900 --> 00:19:37.700
valid and successful for hepatitis C
392
00:19:36.700 --> 00:19:39.900
pharmaceut was a One Drug
393
00:19:39.900 --> 00:19:40.500
Company.
394
00:19:41.300 --> 00:19:44.700
So what is a value for one project One Drug
395
00:19:44.700 --> 00:19:47.200
Company? It is yanet present value,
396
00:19:47.200 --> 00:19:51.100
which you are going to generate out of selling the product multiplied by
397
00:19:50.100 --> 00:19:52.900
the probability gives you the approval.
398
00:19:53.600 --> 00:19:56.900
Now in the first calculations made by Gilead
399
00:19:56.900 --> 00:20:00.700
the selling price of the drug walls 36,000
400
00:19:59.700 --> 00:20:02.500
and in reality
401
00:20:02.500 --> 00:20:05.300
once they acquire the company and they got the approval
402
00:20:05.300 --> 00:20:08.800
from the FDA the double the price the double
403
00:20:08.800 --> 00:20:11.900
the price to 72,000 and why
404
00:20:11.900 --> 00:20:14.600
because the alternative on a
405
00:20:14.600 --> 00:20:17.500
health care point of view is a lever transplant
406
00:20:17.500 --> 00:20:21.200
which costs by itself 200,000 and
407
00:20:20.200 --> 00:20:24.300
which requires an animal treatment forever
408
00:20:23.300 --> 00:20:27.400
for the rest of your life which costs 40,000
409
00:20:26.400 --> 00:20:29.500
per year. So you understand
410
00:20:29.500 --> 00:20:32.500
that if you propose to completely cures disease
411
00:20:32.500 --> 00:20:35.700
for 72,000. Everybody's going
412
00:20:35.700 --> 00:20:38.600
to accept on the financial point of view. There were some negative
413
00:20:38.600 --> 00:20:41.000
consequences on a reputation point of view
414
00:20:41.900 --> 00:20:44.300
forget now, if you look at the revenues generated by
415
00:20:44.300 --> 00:20:47.300
the portfolio of products propose and
416
00:20:47.300 --> 00:20:50.300
Soul by Gilead on the treatment of the disease
417
00:20:50.300 --> 00:20:52.600
you see that there is an increase in Revenue.
418
00:20:53.600 --> 00:20:56.300
And it goes down and why does
419
00:20:56.300 --> 00:20:59.400
it go down simply because your product is absolutely
420
00:20:59.400 --> 00:21:03.400
great and people are cured forever. So
421
00:21:02.400 --> 00:21:06.200
the disease simply disappears.
422
00:21:05.200 --> 00:21:08.500
It's a disease disappears. The cash
423
00:21:08.500 --> 00:21:11.400
flow is also are disappearing. So it's a one
424
00:21:11.400 --> 00:21:14.000
drug product and there's no growth option behind that.
425
00:21:14.700 --> 00:21:17.100
Interestingly When You observe the evolution of the
426
00:21:17.100 --> 00:21:20.500
Gilead stock price, the company's acquiring
427
00:21:20.500 --> 00:21:23.700
farmer said doublings are selling price making a
428
00:21:23.700 --> 00:21:26.200
lot of money and a stuck price of Gilead. He's
429
00:21:26.200 --> 00:21:29.800
going to go skyrocketing especially against a
430
00:21:29.800 --> 00:21:32.800
NASDAQ and then what happens farmer said
431
00:21:32.800 --> 00:21:35.700
is over farmer said he's over because you get
432
00:21:35.700 --> 00:21:38.200
to the end of the story and then the stock
433
00:21:38.200 --> 00:21:41.100
price collapses and if you look at the evolution of growth
434
00:21:41.100 --> 00:21:44.200
options at Gilead you understand that farmer said
435
00:21:44.200 --> 00:21:45.200
was a one shot
436
00:21:45.900 --> 00:21:48.500
and gross options are not that very big in
437
00:21:48.500 --> 00:21:50.000
their market value of the company.
438
00:21:51.300 --> 00:21:54.900
Let's go back to this point. What about existing assets at
439
00:21:54.900 --> 00:21:57.200
Amgen? The company's is
440
00:21:57.200 --> 00:22:00.200
marketing two products, which you can for about one
441
00:22:00.200 --> 00:22:03.200
third of the revenues, but when you look at when the
442
00:22:03.200 --> 00:22:06.600
products where developed and when this is
443
00:22:06.600 --> 00:22:09.300
started marketing and commercializing these products you understand
444
00:22:09.300 --> 00:22:12.300
that the company is under the threat of a patent Cliff
445
00:22:12.300 --> 00:22:15.200
the patent Leaf is when your pattern gets too
446
00:22:15.200 --> 00:22:18.200
maturity and the free cash flow falls down because there
447
00:22:18.200 --> 00:22:21.600
will be generics and so on so forth, of course the company announces
448
00:22:21.600 --> 00:22:24.600
four phase three positive results
449
00:22:24.600 --> 00:22:27.800
for project, but it's only phase
450
00:22:27.800 --> 00:22:30.300
three positive results not yet approval just one
451
00:22:30.300 --> 00:22:33.200
approval in 2022. So the question
452
00:22:33.200 --> 00:22:36.600
is grow the sales grows revenues grow the
453
00:22:36.600 --> 00:22:37.500
pipeline.
454
00:22:38.300 --> 00:22:42.100
And Horizon is proposing plenty of growth option
455
00:22:41.100 --> 00:22:44.500
as a complement to the current existing
456
00:22:44.500 --> 00:22:47.300
asset, of course with one product which was
457
00:22:47.300 --> 00:22:50.200
launched in 2022 the generate more than
458
00:22:50.200 --> 00:22:53.200
two billion dollars in sales, which is more than 50% of
459
00:22:53.200 --> 00:22:56.700
the total revenues of the company. There is another product which
460
00:22:56.700 --> 00:22:59.600
was launched in 2010 for the treatment of the gout
461
00:22:59.600 --> 00:23:02.700
and it represents 20% of the revenue
462
00:23:02.700 --> 00:23:04.300
700 million dollars.
463
00:23:05.200 --> 00:23:08.400
But what is interesting in the communication of the company is that they
464
00:23:08.400 --> 00:23:12.200
mentioned that there is no competitor product. No
465
00:23:11.200 --> 00:23:14.600
FDA approved competitors so
466
00:23:14.600 --> 00:23:18.000
far. There are some under process of approvement
467
00:23:17.600 --> 00:23:20.700
products and so on so forth but so far there
468
00:23:20.700 --> 00:23:23.700
are on the planet. So as far as a company's existing assets
469
00:23:23.700 --> 00:23:26.500
are concerned life is okay, but in addition
470
00:23:26.500 --> 00:23:28.300
to that there are plenty of growth options.
471
00:23:29.200 --> 00:23:32.300
They have five products under phase three
472
00:23:32.300 --> 00:23:35.800
phase three is quite close to completion and approval.
473
00:23:35.800 --> 00:23:38.400
They have 11 products in
474
00:23:38.400 --> 00:23:41.100
face, too. So you understand that the company is
475
00:23:41.100 --> 00:23:45.000
a collection is a portfolio of growth options. Now,
476
00:23:44.200 --> 00:23:47.300
what is a value of a company at large?
477
00:23:47.300 --> 00:23:50.600
And what is the value of a pharmaceutical company It's a
478
00:23:50.600 --> 00:23:53.400
combination of probability because you
479
00:23:53.400 --> 00:23:56.600
are plenty of projects product in face to face three.
480
00:23:56.600 --> 00:23:59.400
The question is what is a probabilities that they
481
00:23:59.400 --> 00:24:01.700
receive the approval from the FDA.
482
00:24:02.400 --> 00:24:06.300
And probability is combined with sustainability.
483
00:24:05.300 --> 00:24:08.400
What is sustainability about
484
00:24:08.400 --> 00:24:11.400
durability and during business
485
00:24:11.400 --> 00:24:14.800
is your ability to capitalize on your skills
486
00:24:14.800 --> 00:24:18.000
in house so that you can develop and
487
00:24:17.600 --> 00:24:20.600
manage products so that you can I don't
488
00:24:20.600 --> 00:24:23.600
Define targets you can identify the
489
00:24:23.600 --> 00:24:26.800
right targets and pay the right price and integrate in
490
00:24:26.800 --> 00:24:30.100
your business operations and sustainability is
491
00:24:29.100 --> 00:24:32.800
very much about the growth options together
492
00:24:32.800 --> 00:24:35.400
with the quality of execution when it
493
00:24:35.400 --> 00:24:38.000
is a plan to the current existing assets.
494
00:24:38.800 --> 00:24:42.100
When I make the calculations for Horizon to
495
00:24:41.100 --> 00:24:44.500
Rapid existing assets, I would
496
00:24:44.500 --> 00:24:48.200
name that the first part of the Enterprise Value growth
497
00:24:47.200 --> 00:24:51.000
during ten years. It was accounting for 40% which
498
00:24:50.200 --> 00:24:53.700
is quite High fear the growth options
499
00:24:53.700 --> 00:24:56.400
were counting for 60% of the value.
500
00:24:56.400 --> 00:24:59.500
If you're experiencing this kind of calculation, you
501
00:24:59.500 --> 00:25:03.300
lose that grows options. Sometimes it's not 60% It's 80%
502
00:25:02.300 --> 00:25:05.300
of the value of the company. But what
503
00:25:05.300 --> 00:25:08.600
about these growth options? How do you generate? How do
504
00:25:08.600 --> 00:25:11.800
you I don't Define how do you exercise growth options
505
00:25:11.800 --> 00:25:14.900
with management and technical skills
506
00:25:14.900 --> 00:25:17.900
the ability to identify the ability
507
00:25:17.900 --> 00:25:20.500
to integrate the ability to properly run
508
00:25:20.500 --> 00:25:23.700
these growth options. And so
509
00:25:23.700 --> 00:25:26.600
you understand that the value comes from the growth options
510
00:25:26.600 --> 00:25:29.500
and growth options about skills. It's about human
511
00:25:29.500 --> 00:25:32.200
capital. It's about people so the value
512
00:25:32.200 --> 00:25:36.900
of any company is about human assets business
513
00:25:35.900 --> 00:25:38.300
as usual. No surprise.
514
00:25:39.300 --> 00:25:39.900
Thank you very much.
Hello and welcome to this film which is devoted to the acquisition by Amgen of horizon therapatics.
We are in an industry which is name Pharmaceuticals.
And it seems that they are plenty of acquisition in the right time for shopping in the Biotech Industry.
You all remember about fights a fighter made a lot of money on the vaccines against the covid-19 when you make a lot of money.
What can you do? You can return the cash to the shareholders or you can reinvest in the development of the company.
Invest and grow research development Acquisitions and so on and basically it is a solution which has been adopted the strategy of Pfizer Pfizer announced in October 2022 the acquisition of biohaven for 11.6 billion dollars and very recently in March the acquisition of CJ and for 43 billion dollars.
Now when you get cash from something which is maybe exceptional hopefully the question is what do you do with the Monet again return or invest traditional story now Amgen is offering 27.8 billion dollars for Horizon to Rapides.
It was announced in December 2022 and it is ongoing.
The reason for Amgen to buy Horizon is they want to develop they want to expand in rare diseases treatments.
Us strategy now, I'm Jen was created and established around 1980 and they received the first FDA approval online 1989 for a drug with name was epogen.
You understand that in the pharmaceutical industry.
It takes time before the mermaid you start investing in research and development and getting through phase one two, three and approval it takes time.
And then in the meantime, you have all these products which are in the pipeline.
The company is in a technology, which is his name recombinant DNA.
It's about biotech.
It's about genetics.
The company has been quite successful so far.
They had a little bit of accident in 2012 because the campaign was accused of making some indications proposing to customers indications, which had not been approved by the FDA and illegal marketing practices a company had to pay one hand and 50 million dollars for penalties and 612 million dollars to close all the complaints related with this really bad process.
That being said the company developed a strategy which consists in R&D.
Are a debit also plenty of Acquisitions companies firms cooperations and formulas.
To give you some examples 2015 the Zima for 1.6 billion biringer ingelheim's the myeloma treatment in 2016 2017 celga and the old Sarah program for 13.4 billion 20.5% of by Gene Beijing which is a kind of phonetical joke because a company is located in Beijing for 2.7 billion.
It was in 20 20 21 five prime plus plus four three point five billion.
And the last one last year camel Centrics for three point seven billion.
Now Horizon is much more but you know, it's a kind of continuation in investment.
You can consider that the company is very much investing but it's also returning plenty of cash to shareholders.
And so far the sales the revenue are not growing at a high rate the kagger increasing sales.
I'm Jen from 2019 to 2022 is just 4% per year and it was less last year.
So of course there is a list of Acquisitions and if you take these four years the sub up to 23 billion dollars, but in the meantime, we share BuyBacks during the same years and dividend so cash return to shareholders account for 38 billion.
So 15 billion more given back to shareholders as opposed to reinvested in business operations.
It's quite important to understand where the company stands today.
Now if you compare and Benchmark, I'm Jen and Horizon.
Amgen is bigger the sales in 2022 where 26 billion and for Horizon 3.6 billion.
We'll see in a minute based on one product.
But the sales grows, he's just 1% at Amgen when it is 12% currently for Horizon a discussion on growth is for layer.
Now on a commercial point of in terms of returns sales.
The return sales is much higher than the one for Horizon.
So 36% as opposed to 17% the return Capital you remember the performance indicator is 29% and only 12% for Horizon.
But you remember that to calculate the return Capital you divide the operating income a bit by Capital employed in the capital employed you have good.
Will you are Branch you have catalyzed R&D acquired R&D and so on so forth.
So the consequence of Acquisitions, if you get rid of that in the calculation of the capital employed you get to something which is operating Capital employed and then you can calculate the return which is generated by your business operations.
Whatever the cost you paid for the Acquisitions and then it kind of return on investment.
I often name that return investment.
It's more than 500% for MJ.
So you understand that what is penalizing the company is Goodwill and Brands and capitalize are the and so on so forth.
The return investment for Horizon is only quotes 78% which is still very high the consequence of all these metrics is that the market cap for ham Jen is 129 billion.
It's a very big company with Wrong capitalization as far as Horizon to Rapides is concerned the market cap was 14 billion before the offer made by Amgen and today it's 25 billion dollars.
So it's smaller.
That's quite normal if you look at the metrics.
We had a look at the story of Amgen.
Now Horizon therapatics is a very specific Company.
The company was created in 2004 by a gentleman whose name is Tim Walbert is chairman of the board chief executive officer founder and customer and patient now at the origin of horizon zerapatics, there's the idea of Team Wahlberg and the idea comes from the fact that is suffering from these rare diseases.
One of them only want to develop an offer a portfolio of treatments for these rare diseases.
You understand the communication point of view that when the CEO says I am the one who is using the same treatment as you the customers, this is quite strong.
Now the company is very much based in the United States 97% of sales and revenues are generated by the company in the United States, but the company's paying its taxes in Ireland because in 2014 the company runs something which is never tax inversion and they did it three days before all the legislation changes about these possibility to change the localization of the head office.
In fact Horizon acquired vidara Therapeutics in Ireland for 660 million dollars.
This is not the important figure and they moved the head office to Ireland at the consequence.
Now the company's paying taxes on the basis of 15% as opposed to 35% at that time.
When you save 20% of tax, what do you do with the money it's cash which is available.
And the company says I pay less taxes.
I have more cash available to make Acquisitions for the sake and the wealth of my dear beloved shareholders.
Now, you understand that there are some questions behind that put yourself in the shoes of the US government.
You're in charge of trying to prevent the companies to move from USA to anywhere else kinds of tax Havens, right? What would you recommend to change in the legislation? Would you recommend to change the law unforbids this kind of process now, it's forbidden and you're not allowed to move your head office tax Wise from I don't know, New York to Dublin.
Second alternative.
Do you reduce the corporate tax rate? So that companies have less motivation to move abroad you understand that if the situation is currently 35 as opposed to 15.
The motivation is high if it is 25 or 20 the motivation is less because it's costly to move the head office.
Now, of course, there's no one best way but just take a couple of minutes thinking about the implications of these two Alternatives.
If you decide to implement one as opposed to the other, it's quite an interesting intellectual process.
Now, let's move on with Horizon Therapeutics.
The capital is paying less taxes.
So the company holds more cash.
What do you do with the cash make Acquisitions Hyperion torapatics for one point something billion in 20 15 one year after the tax inversion earlier Raptor pharmaceutical for 0.6 billion recently the lrbo for 3 billion.
Interestingly the company tried to take over Diplomat and Diplomat.
It was not successful at all in 2015 Horizon is offering three billion dollars thirty three dollars per share.
Remember this figure to buy 100% of Diplomat shares.
The offer is rejected by the board of Diplomat this as a price is not high enough, of course, they always say that but they are also going to implement a poison pill which is named shareholders rights plan.
If there is a whole style take over and if a Raider holds most and 10% of the share, you are allowed to flood the market with new shares diluting the process and that's just impossible to buy the company.
But this is about a poison pill it was nicely complemented and supported by a decision taken by the superior court of justice in California.
And the quarter just said, hey, you know Horizon you use some confidential information to prepare your takeover on Diplomat, which is absolutely ill.
You're not allowed to do that.
And this is why there was this kind of Justice decision, which was a nice compliment to the poison pill.
What was the story about? A few years before Horizon and Diplomat they made an offer joint offer to buy from Johnson & Johnson a portfolio products including Nucynta.
The art field was rejected the withdraw the offer whatever end of the story but in order to make the offer you need Horizon to know a little bit about papermed and diplomed a little bit about Horizon.
So you have access to confidential information.
Of course, you sign an NDA and so on so forth, but you know, what is happening in the culture of your beloved neighbor later on Diplomat bold Lucinda, which was part of the portfolio and they had one billion dollars lucinta is a painkiller but it belongs to a family of product which is named opioids.
All right, and so the Wall Street Journal are not already in 2015.
Well say, you know opioid it's it's a cash cow, but it's a little bit of problem on a technological unhealth point of views are plenty of Critics on that now Diplomat by his new center and wants to fully benefit from Lucinda.
And says that service regards per share does not reflect the true value of new center and they are right because when Horizon makes the offer it is at 33 dollars a few months later mid 2015 and of 2015 the stock price reaches a high of 125 dollars per share.
This is why Diplomat rejected the board rejected the offer but nucinta is part of opioid and you know all the problems related with that with plenty of death.
This is why later on Diplomat had to sell Nucynta for 10 million dollars acquired one billion dollars Diplomat was really very much in trouble.
They change the name of the company as they moved to assess you changing.
The name does not get rid of problems and issues and today currently the stock price is six dollars per share.
But at the end of the day, it was probably not a bad news for Horizon not to buy the permit.
But let's go back to Horizon.
Now.
There is an acquisition.
There's a price.
Let's try to evaluate the company to evaluate a company you use a free cash flows, which you discount at the weighted average cost of capital free cash flows.
The formula is very well known it's a bit I minus change in working capital requirement inventories and receivables that have payables minus Capital expenditures minus taxes you pay on their bit.
You take their current a bit.
It's what I did by the way in terms of Delta increase in the working capital requirement.
I can't commit to the working capital requirement which I'm multiplied by the current growth rate of the revenues to our present Capital expenditures.
It's about 2% to sales.
It's not very Capital intensive.
It's kind of business.
The free cash flow which you get after this calculation is 880 million dollars.
Now this free cash flow has to be discounted and the way the average cost of capital.
You remember cost of equity time share of equity cost of that time share of that share of that Neil almost zero.
So the walk is the cost of equity to calculate the cost of equity.
You need to know the government born.
Right and you're going to add a risk premium, which is a beta the systematic risk coefficient.
You remember the correlation to stock market index which is supposedly the correlation between the value of the company and macroeconomy conditions and the beta is multiplied by the average historical Market risk premium.
The beta as you see on the graph is about one 36 months beta you remember the 12 months beta is much more for a time.
It's quite stable around one.
No big deal about the calculation work again is cost of equity garment bone rate currently about 3.4 6% for the equity Market which premium which you multiply by one to add 3.4 and you get 9.4% again, the cost of capital does not include any cost of that now once you have calculated the weighted average cost of capital and calculated the current cash flow, you can discount the free cash flows which are going to be generated by the company in the future.
But then there are two situations if the company is at maturity the free cash flow is going to smoothly grow by G percentage and every year and then you have a beautiful formula which tells you that the Enterprise Value is a kind of terminal value because you are at maturity.
It's free cash flow to the multiplied by 1 plus rows divided by walk less grows.
If you remember a bit about many many eggs, it's about geometric series one plus X Plus x to the second power blah blah, which is converging towards the formula which shows on the screen.
Now the question is, what about the growth rate? And then you have to Alternatives, you know, the price rate you calculate the Enterprise Value, you know, the Enterprise Value, then you can calculate the underlying growth rate which justifies the Enterprise Value on the stock market.
If you take a stock price of $62 per share, which is a pre takeover price.
It represents an Enterprise value of 14.4 billion dollars, which is justified by a kind of underline growth of 3.3% Three percent it's less than inflation today.
It's a kind of History called inflation rate for the United States.
So you understand that at the end of the day.
The company was probably under revolved with it by the market.
If you take the offered price for the Takeover, the Enterprise Value is about 27 billion dollars.
And then it is justified by a growth in our revenues by 6.1% 6.1 is kind of inflation plus GDP grows.
No big deal about that.
The problem about the calculation is that the company's definitely not at maturity yet.
This is why you need a second method which is a little bit more sophisticated.
It's a two-step model first high growth second.
Maturity Enterprise Value is a present value of the cash flows when the company is fast growing plus the terminal value of the company you use the same formula with a free cash flow divided by workplace grows, which you discount No big deal.
The question is what is a growth during this first phase and what will be the growth in the long term? I took 12% for the next 10 years, which is a current growth rate.
And I took 2.5% which is a little bit less than inflation for the terminal value calculation and at the end of the day, what do you get you get the same Enterprise Value as a one which is offered today by Amgen.
110 dollars per share as supposed to one hand 16.5 now you understand that the price which is offered by mg and is consistent with you keep on growing at 12% and then a terminal value.
It takes into account 2.5% looks quite reasonable.
But the question is is it the right way to evaluate a company in pharmaceutical industry? When you want to evaluate a company, there's a kind of general rule.
The value for company is the sum of the value of the existing embedded assets put the value of growth options.
To make it simple.
The existing assets are generating the current and near future free cash flows.
But in a long time the value of the company is about exercising growth options.
This is I identifying projects and implementing the growth options, which is going to generate long term free cash flows.
What about these growth option? It's about competences.
It's about skills.
It's about Rd.
It's about human capital.
It's about reputation The credibility of your industry and The credibility of the company within the industry.
All these assets are intangible assets.
It does nothing to do with property plant and equipment in order to understand the difference between an existing asset and a growth option.
There's an interesting case.
You remember any Academy? We studied the acquisition of farmer said by Gilead the treatment which had been developed by pharmaceut was extremely valid and successful for hepatitis C pharmaceut was a One Drug Company.
So what is a value for one project One Drug Company? It is yanet present value, which you are going to generate out of selling the product multiplied by the probability gives you the approval.
Now in the first calculations made by Gilead the selling price of the drug walls 36,000 and in reality once they acquire the company and they got the approval from the FDA the double the price the double the price to 72,000 and why because the alternative on a health care point of view is a lever transplant which costs by itself 200,000 and which requires an animal treatment forever for the rest of your life which costs 40,000 per year.
So you understand that if you propose to completely cures disease for 72,000.
Everybody's going to accept on the financial point of view.
There were some negative consequences on a reputation point of view forget now, if you look at the revenues generated by the portfolio of products propose and Soul by Gilead on the treatment of the disease you see that there is an increase in Revenue.
And it goes down and why does it go down simply because your product is absolutely great and people are cured forever.
So the disease simply disappears.
It's a disease disappears.
The cash flow is also are disappearing.
So it's a one drug product and there's no growth option behind that.
Interestingly When You observe the evolution of the Gilead stock price, the company's acquiring farmer said doublings are selling price making a lot of money and a stuck price of Gilead.
He's going to go skyrocketing especially against a NASDAQ and then what happens farmer said is over farmer said he's over because you get to the end of the story and then the stock price collapses and if you look at the evolution of growth options at Gilead you understand that farmer said was a one shot and gross options are not that very big in their market value of the company.
Let's go back to this point.
What about existing assets at Amgen? The company's is marketing two products, which you can for about one third of the revenues, but when you look at when the products where developed and when this is started marketing and commercializing these products you understand that the company is under the threat of a patent Cliff the patent Leaf is when your pattern gets too maturity and the free cash flow falls down because there will be generics and so on so forth, of course the company announces four phase three positive results for project, but it's only phase three positive results not yet approval just one approval in 2022.
So the question is grow the sales grows revenues grow the pipeline.
And Horizon is proposing plenty of growth option as a complement to the current existing asset, of course with one product which was launched in 2022 the generate more than two billion dollars in sales, which is more than 50% of the total revenues of the company.
There is another product which was launched in 2010 for the treatment of the gout and it represents 20% of the revenue 700 million dollars.
But what is interesting in the communication of the company is that they mentioned that there is no competitor product.
No FDA approved competitors so far.
There are some under process of approvement products and so on so forth but so far there are on the planet.
So as far as a company's existing assets are concerned life is okay, but in addition to that there are plenty of growth options.
They have five products under phase three phase three is quite close to completion and approval.
They have 11 products in face, too.
So you understand that the company is a collection is a portfolio of growth options.
Now, what is a value of a company at large? And what is the value of a pharmaceutical company It's a combination of probability because you are plenty of projects product in face to face three.
The question is what is a probabilities that they receive the approval from the FDA.
And probability is combined with sustainability.
What is sustainability about durability and during business is your ability to capitalize on your skills in house so that you can develop and manage products so that you can I don't Define targets you can identify the right targets and pay the right price and integrate in your business operations and sustainability is very much about the growth options together with the quality of execution when it is a plan to the current existing assets.
When I make the calculations for Horizon to Rapid existing assets, I would name that the first part of the Enterprise Value growth during ten years.
It was accounting for 40% which is quite High fear the growth options were counting for 60% of the value.
If you're experiencing this kind of calculation, you lose that grows options.
Sometimes it's not 60% It's 80% of the value of the company.
But what about these growth options? How do you generate? How do you I don't Define how do you exercise growth options with management and technical skills the ability to identify the ability to integrate the ability to properly run these growth options.
And so you understand that the value comes from the growth options and growth options about skills.
It's about human capital.
It's about people so the value of any company is about human assets business as usual.
No surprise.
Thank you very much.